Abstract:The formulation of betamethasone-17-valerate (BV) into topical medicines presents a significant challenge for the formulation chemist. The substance is susceptible to acid and base catalyzed isomerization in aqueous environments, which results in valerate transesterification from carbon 17 to carbon 21 of the steroid ring system. This acyl migration process is of significant clinical importance since the 21-valerate ester possesses only a fraction of the potency of the 17-valerate parent compound. Isomerization of BV should therefore be reduced to a minimum through design of a suitable drug vehicle. In this study, the effect of varying the concentration of several excipient components on the isomerization rate of betamethasone valerate in a model hydrophilic cream has been investigated. These excipients include the emulsifier macrogolstearylether-20/21, the co-emulsifier cetylstearyl alcohol and the thickening agent hydroxyl propyl methylcellulose. Additionally, the influence of pH, the presence of the antioxidant, alpha-tocopherol, as well as the chelating agent, disodium edetate, on the stability of the formulation have been investigated. Trial drug product formulations, which were designed to investigate the influence of the above-mentioned components/parameters were manufactured and their stability was tested according to current ICH Guidelines. The content, purity and crystalline structure of the active substance in these formulations was analyzed by a combination of HPLC and microscopy techniques. The study demonstrates that the rate of isomerization of betamethasone valerate depends significantly on the concentration of emulsifier used in the cream formulation. At higher concentrations of emulsifier the isomerization proceeds rapidly with significant degradation over a period of weeks, whereas at lower concentrations significant degradation may not be observed, even after several years' storage. The influence of the emulsifier has been shown to be independent of the pH value of the aqueous phase of the cream. These findings have not been reported in previous literature reports on this topic, which have tended to focus on the influence of pH. The results are likely to be of interest to pharmaceutical chemists working on the formulation of glucocorticoids as well as to local- and hospital pharmacists who carry out the practice of dilution of proprietary corticoid preparations, where the choice of diluent is likely to be critical for ensuring the stability of the diluted product.

Development of Spectrophotometric Method for the Quantitative Determination of Betamethasone 17-Valerate in Creams

LC–MS/MS determination of betamethasone and its phosphate and acetate esters in human plasma after sample stabilization

Development And Validation of UV-VIS Spectrophotometric Method for Determination of Triamcinolone from Dissolution Media

The First Validation HPTLC Method for Simultaneous Estimation of Beclomethasone Dipropionate and Fusidic Acid in Pure and Pharmaceutical Dosage Form

Formulation factors affecting the isomerization rate of betamethasone-17-valerate in a developmental hydrophilic cream – a HPLC and microscopy based stability study

Development of Double-Layer Poly (amino Acid) Modified Electrochemical Sensor for Sensitive and Direct Detection of Betamethasone in Cosmetics

Development and validation of a high-performance thin-layer chromatography method for the quantification of adapalene and preservative phenoxyethanol in gel formulation—application to stability studies

Simultaneous Determination of Chloramphenicol and Betamethasone in Xinfu Cream by HPLC

New analytical LC–MS/MS method for fluconazole and ivermectin estimation in combined pharmaceutical dosage form: development and validation

A Stability Indicating Reverse Phase High Performance Liquid Chromatography Method for Simultaneous Estimation of Hydroquinone, Hydrocortisone and Tretenoin in Cream Formulation

Analysis of betamethasone, dexamethasone and related compounds by liquid chromatography/electrospray mass spectrometry

An Eco-Friendly HPLC-DAD Determination of Corticosteroids Combined with Other Therapeutic Compounds in Bulk and Topical Formulations: Greenness and Whiteness Assessment

Development and validation of a high-performance thin-layer chromatography assay for the analysis of tacrolimus ointments

Development and validation of a new spectrofluorimetric method for the determination of some beta-blockers through fluorescence quenching of eosin Y. Application to content uniformity test

A stability indicating RP-HPLC-UV assay method for the simultaneous determination of hydroquinone, tretinoin, hydrocortisone, butylated hydroxytoluene and parabens in pharmaceutical creams

Determination of Chloramphenicol and Triamcinolone Acetonide in Compound Triamcinolone Cream by HPLC

Validation of a screening method for corticosteroids in doping analysis by liquid chromatography/tandem mass spectrometry

Validated derivative and ratio derivative spectrophotometric methods for the simultaneous determination of levocetirizine dihydrochloride and ambroxol hydrochloride in pharmaceutical dosage form

Chemometrics-assisted spectrophotometric method development and validation for simultaneous estimation of emtricitabine, tenofovir alafenamide fumarate, and dolutegravir sodium in dosage form

Indirect Spectrophotometric Determination of Cefalexin monohydrate, Ceftriaxone Sodium and Cefotaxim Sodium in Pharmaceuticals Using N-Bromosuccinimde and Evans Blue Dye

Development and validation of a liquid chromatography–electrosprayionization mass spectrometric method for the determination of dexamethasone in sheep plasma